## CBOE: Cboe Global Markets, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 -1.9% below STRENGTH zone (4.0-10.0%); PEG 2.09 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($238.94)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Cboe Global Markets (CBOE) Valuation After Barclays Upgrade on Derivatives Growth and Strategic Refocus**
- Source: Simply Wall Street | 20251216T140812 | Somewhat-Bullish | Relevance: 100%
- Barclays upgraded Cboe Global Markets (CBOE) to Overweight, citing strong performance in its index options and increased retail options activity. Despite a robust share price run and near-record highs, the company's valuation is debated, with Simply Wall St's narrative suggesting it's 5.8% undervalued, whereas a DCF model indicates it's overvalued. The article highlights Cboe's consistent double-digit revenue growth in its Data Vantage segment and strategic refocus on core derivatives.

**2. Cboe Global Markets (CBOE) Valuation After Barclays Upgrade on Derivatives Growth and Strategic Refocus**
- Source: Simply Wall Street | 20251216T140119 | Somewhat-Bullish | Relevance: 100%
- Barclays upgraded Cboe Global Markets (CBOE) to Overweight, citing its strong index options engine, increased retail options activity, and a sharpened focus on core derivatives. Despite a strong performance year-to-date and near-record highs, the stock's valuation is a key debate, showing a narrative fair value of $262.08 (moderately undervalued) versus a DCF model's $201 (overvalued). The narrative emphasizes Cboe's double-digit revenue growth in Data Vantage and operational efficiencies, while the DCF model suggests potential overvaluation if growth or margins underperform.

**3. Cboe Global Markets (BATS:CBOE) - Stock Analysis**
- Source: Simply Wall Street | 20251214T160755 | Neutral | Relevance: 100%
- This article provides a detailed stock analysis of Cboe Global Markets (CBOE), highlighting its operational segments, financial health, and future growth prospects. It includes recent news, dividend information, and market performance compared to industry benchmarks, noting its stability and potential for future growth driven by derivatives and international expansion.

**4. How Investors Are Reacting To Cboe Global Markets (CBOE) Barclays Upgrade And 24-Hour Russell 2000 Options**
- Source: Simply Wall Street | 20251214T150759 | Somewhat-Bullish | Relevance: 100%
- Barclays recently upgraded Cboe Global Markets to Overweight, citing strong growth in index options and retail options activity, alongside a focus on core derivatives. Cboe also plans to extend Russell 2000 Index options to nearly 24-hour trading by February 2026, enhancing access to its proprietary index products. These developments reinforce Cboe's growth narrative, although investors should consider its concentration risk in core index franchises and potential fee pressures.

**5. Thrivent Financial for Lutherans Has $27.24 Million Position in Cboe Global Markets, Inc. $CBOE**
- Source: MarketBeat | 20251216T135219 | Neutral | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in Cboe Global Markets, Inc. (NASDAQ:CBOE) by 44.3% in the second quarter, now owning 116,859 shares valued at $27.24 million. This move comes as Cboe Global Markets reported strong quarterly earnings, beating consensus estimates with an EPS of $2.67 and a 13.8% year-over-year revenue increase. The company also recently paid a quarterly dividend of $0.72 per share, and analysts maintain a "Hold" rating with an average target price of $245.15 for the stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Barclays | $302 | $273 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Barclays | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (+0.0%)
- Blackrock Inc.: 9.0% (-2.7%)
- Alliancebernstein L.: 6.1% (-31.2%)
- State Street Corpora: 4.5% (+2.1%)
- FMR, LLC: 4.3% (+62.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.09 elevated, pricing in significant growth expectations. Forward P/E 22.9x stretched relative to 5% growth. Quality metrics strong (ROE 22%, margin 21%). Analyst sentiment positive (1 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.1B |
| Beta | 0.35 |
| 52W Range | $187.30 - $262.98 |
| Short Interest | 3.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.09 |
| Forward P/E | 22.9 |
| Current P/E | 24.0 |
| YoY Growth | 4.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -4.8% to -1.9% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.8pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Underperforming sector by 4.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-1.23), momentum weakening. RSI neutral at 44. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.85% (CS: 26) | Neutral |
| RSI_14 | 44.3 | Neutral |
| MACD Histogram | -1.23 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.061x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $248.64
- **Stop Loss:** $238.94 (3.9% risk)
- **Target:** $258.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 123
- **Position Value:** $30,582.72
- **Portfolio %:** 30.58%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-06 (Est: $2.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.53 | $2.67 | +5.6% |
| 2025Q2 | $2.44 | $2.46 | +0.6% |
| 2025Q1 | $2.36 | $2.50 | +5.8% |
| 2024Q4 | $2.12 | $2.10 | -0.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*